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Abstract
Cancer is one of the leading causes of death in the world, and chemotherapy plays an important
role in cancer treatment. However, serious adverse effects of chemotherapy could jeopardize the
efficacy of the treatment as well as patients’ quality of life. In order to remit this problem, a wellcharacterized herbal medicine, YIV-906 (KD018/PHY906), was developed as a combination
therapy with chemotherapy. It is based on a traditional Chinese herbal formulation (Huang-QinTang) that treats diseases related to gastrointestinal disorders and was investigated in a two-arm
clinical trial for metastatic colorectal cancer (mCRC). A previous analysis done by Sun et al.
showed significantly improved progression-free survival (PFS) in YIV-906 adjuvant group for
mCRC patients who completed at least three cycles of treatment. This study confirmed these
results using data from the same clinical trial and evaluated differences in health-related quality of
life (HR-QoL) and metabolite profiles between experimental and control groups. The healthrelated quality of life was not significantly different between groups within four cycles, whereas
from 5 to 8 cycles, patients in the YIV-906 group had significantly greater HR-QoL compared to
those in the control group. To explore the mechanism of YIV-906’s impact on PFS or HR-QoL,
expression levels of 72 metabolites were collected, and 4 out of these 72 metabolites were
significantly impacted by YIV-906. In the future, analyses should confirm these results in larger
clinical trials and should explore whether the metabolites identified here are related to improved
PFS and HR-QoL in the YIV-906 group.
Keywords: YIV-906, PFS, health-related quality of life, metabolites.
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1. Introduction
Due to various factors such as population growth and aging, the global burden of cancer
has been increasing over time. According to the World Health Organization (WHO), the
cancer burden has risen to 18.1 million new cases and 9.6 million deaths in 2018 worldwide
[1]. Colorectal cancer (CRC) is the fourth leading cause of death in the world, and
metastases (mCRC) are the major cause of mortality in this cancer patients population [2,
3]. According to data from 2008-2014 obtained from the Surveillance, Epidemiology, and
End Results Program (SEER), 21% of colorectal cancer cases were diagnosed as distant
metastatic disease, for which the 5-year survival is only 13.8% [4]. Chemotherapy plays
an important role in treating patients with CRC. Currently, the first-line modern
chemotherapy for mCRC is fluorouracil plus leucovorin in combination with oxaliplatin
(FOLFOX), while FOLFIRI (5-fluorouracil + leucovorin + irinotecan) is the second most
effective chemotherapy [5]. Combinations based on irinotecan (CPT-11) are more effective
than CPT-11 alone, and monoclonal antibodies (bevacizumab, cetuximab, and
panitumumab) are usually used as adjuvants in mCRC treatment [2].
However, chemotherapy is usually associated with serious adverse effects, such as diarrhea,
nausea, and vomiting [6], which could undermine the effect of the therapy by preventing
patients from escalating doses or additional courses of the treatment. Other than the
efficacy of the treatment, patients’ quality of life would be largely lowered. Therefore,
medications that can ameliorate these adverse effects without compromising anti-tumor
efficacy of the treatment could not only make cancer therapy more effective and efficient,
but also improve patients’ quality of life during treatment [7].
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YIV-906 (KD018 / PHY906) is currently being developed to be an adjuvant for
chemotherapy aiming to reduce the side effects associated with cancer chemotherapy and
improve the effectiveness of the treatment as well as patients’ quality of life. YIV-906 is
based on a traditional Chinese herbal formulation, Huang-Qin-Tang (HQT), which consists
of four herbs --- Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, Scutellaria
baicalensis Georgi, and Ziziphus jujuba Mill. HQT has been documented for nearly 1800
years for treating common gastrointestinal diseases, like diarrhea, abdominal spasms, fever,
headache, vomiting, nausea, and other symptoms. YIV-906 is a pharmaceutical grade of
HQT, whose raw herbal ingredients are strictly picked by experienced herbalists and
manufactured according to current Good Manufacturing Practice (cGMP) [8]. It has not
only been tested in several different animal cancer models in the laboratory, but also in six
phase I/II and one phase II clinical trials for multiple types of cancers, such as metastatic
colorectal cancer [9, 10], advanced hepatocellular carcinoma [11], advanced pancreatic
cancers [12,13] and rectal cancer [14].
Some analyses have been done previously on the difference of progression-free survival
(PFS) between patients who did and did not take YIV-906 with CPT-11, and the results
showed that, among patients who finished at least 3 cycles of the treatment, YIV-906
adjuvanted chemotherapy could improve patients’ PFS significantly compared to
chemotherapy alone [credit to Dr. Jiehuan Sun and Peidrin Cheng, et al.]. To confirm this
result, we performed survival analysis using the same data source the impact of YIV-906
on health-related quality of life (HR-QoL) was also examined to test if YIV-906 could
alleviate adverse events associated with chemotherapy and improve patients’ lives during
cancer treatment. Furthermore, we analyzed the metabolomic profiles with the intention to
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find metabolites correlated to HR-QoL or PFS and seek clues for potential explanations of
HR-QoL changes and methods of PFS prediction for mCRC patients treated by
chemotherapy.
The data used in this study were obtained from a phase II colorectal trial of YIV-906 named
“A Phase II Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical
Study of KD018 (PHY906) as a Modulator of Irinotecan Chemotherapy in Patients with
Metastatic Colorectal Cancer”. It included two clinical sites, University of Pittsburgh
Cancer Institute and Yale Cancer Center. All patients recruited into the trial received the
combination of irinotecan plus bevacizumab and were randomized to taking either YIV906 (experimental group) or placebo (control group). Each cycle of therapy was defined as
2 weeks, and patients would continue to be treated until cancer progressed or unacceptable
toxicity occurred. The original study planned to recruit up to 108 patients with 54 patients
being randomized to each treatment arms. However, due to the change of the protocol for
the mCRC first line treatment, the study was forced to stop after obtaining 26 subjects (1:1).
[15]
Progression-free survival (PFS) was one of the endpoints of this study, and information of
hundreds of different biomarkers was collected at the beginning of every treatment cycle,
including metabolites, cytokines, and gene mutations. Prospective evaluation of the effect
of YIV-906 on health-related quality of life (HR-QoL) was recorded at each cycle as well.
The detailed HR-QoL instruments used in the study, such as Symptom Distress Scale
(SDS), Emotional Distress Thermometer (EDT), and Diarrhea subscale, and score
interpretation for each of them are attached as in Appendix A. Trial Outcome Index (TOI)
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was calculated using some of those instruments mentioned above and was taken as the
overall indicator of HR-QoL in the study (higher score indicates better HR-QoL).
2. Methods
2.1 Data Sets
All information used in this study was obtained from the clinical trial “A Phase II MultiCenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Study of KD018 (YIV906) as a Modulator of Irinotecan Chemotherapy in Patients with Metastatic Colorectal
Cancer”. In the study, one patient was excluded due to compliance issues, and only patients
who completed at least three cycles of treatment (PFS > 42 days) were included in the
analysis. The total number of patients involved in this study is 21 (12 in CPT-11 arm; 9 in
CPT-11/YIV-906 arm), but it may change slightly in each different analysis due to missing
data, which are specified in each section below.
2.2 Survival Analysis
Progression-free survival time was one of the endpoints of the trial, which was defined as
the time from the beginning of cycle 1 to cancer progression. All 21 patients were included
in the survival analysis. The Kaplan-Meier survival curves were plotted followed by the
log rank test to compare differences in the survival experience across two treatment groups
overall as well as in each gender group. The Kaplan-Meier survival curves and log rank
test were generated using SAS 9.4.
2.3 Health Related Quality of Life
The trial outcome index which reflected overall well-being was chosen for the analysis of
HR-QoL. Due to incomplete data collection, HR-QoL information of 2 patients in CPT-
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11/YIV-906 arm (both completed more than 10 cycles treatment) and 1 patient in the CPT11 arm (completed 6 cycles treatment) was missing. Thus, the total sample size of HR-QoL
comparison analysis is 18 individuals (11 in CPT-11 arm; 7 in CPT-11/YIV-906 arm). As
the treatment cycle increased, the number of patients staying in the study decreased because
of cancer progression or missing data (see Table 3-2-1).
The TOI scores for each patient in two treatments were plotted in SAS 9.4. The mean TOI
scores of two groups at each cycle were also plotted to compare the overall trend of changes.
Student’s t-test was used to conduct point comparison for two groups at the cycles that had
events (cancer progression) happened and the total patient number was no less than 10.
2.4 Metabolites
In order to assess the metabolomic profiles associated with CPT-11 and YIV-906 treatment,
the levels of hundreds of metabolites were collected at the beginning of each treatment
cycle. After cleaning out missing data, the information of 72 different metabolites from 21
individuals (12 in CPT-11 arm; 9 in CPT-11/YIV-906 arm) was analyzed for the
metabolomic profile evaluation.
For each metabolite, the mean for each group at different cycles was plotted and repeatedmeasures ANOVA was conducted to compare the difference of the means between two
groups over cycles. Due to the large number of metabolites and small sample size, False
Discovery Rate (FDR) was used to avoid increased false positive rate when pursuing
multiple inferences. [16] The analyses of metabolites were performed using the R
programming platform (R 3.5.1).
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3. Results
3.1 Survival Analysis
Of the 21 patients who were included in the survival analysis, one patient in the CPT11/YIV-906 treatment group did not show cancer progression at the end of the trial (8/9)
while all the patients in the control group had disease progression (12/12). According to
the overall Kaplan-Meier curve (Figure 3.1.1), the progression-free survival (PFS) curves
of two treatment group were completely separated, and the progression-free survival
experiences were statistically significantly better in the CPT-11/YIV-906 group [174 days
median PFS; 95% CI (confidence interval): 98 to 378 days] compared to the CPT-11 group
[97.5 days median PFS; 95% CI: 42 to 162 days] (p = 0.0096). This result was consistent
with the results obtained from the previous analyze concluded by Dr. Jiehuan Sun and
Peidrin Cheng [unpublished results].
To determine if the differences in PFS was influenced by gender, stratified Kaplan-Meier
curves were plotted (Figure 3.1.2). Within this sample, 33.33% (7 individuals) were
males and females account for 66.67% (14 individuals). According to the plots, patients
in the CPT-11/YIV-906 treatment group had significantly better progression-free survival
experience among both males and females with stratified log rank test p-value of 0.0067.
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Figure 3.1.1 Overall Kaplan-Meier curves for two treatment groups

*treat: 0 --- CPT11; 1 --- CPT11/YIV-906
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Figure 3.1.2 Stratified Kaplan-Meier curves by gender for two treatment groups
For females:

For males:

*treat: 0 --- CPT11; 1 --- CPT11/YIV-906
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3.2 Health Related Quality of Life
In the CPT-11 group, the trial outcome index (TOI) scores of the 11 patients differed from
50 to 100 and most of them were within 60-80, while 6 out of the 7 patients in the CPT11/YIV-906 group had their TOI score higher than 70 most of the time during the treatment.
Within the first 4 cycles of treatment, most of the patients in both groups had a relatively
stable health-related quality of life (HR-QoL) except patient 15 in the control group and
patient 4 in the experimental groups who experienced a decrease by almost 20 points. After
cycle 5, the HR-QoL of most of the patients in the experimental group stayed steadily
above 60. The TOI score for patient 19 increased by almost 20 points after 6 cycles of CPT11/YIV-906 treatment. However, there were large variations in HR-QoL trends for each
patient in the CPT-11 group. Three out of 6 patients’ HR-QoL became worse as the
treatment went on. For the rest of the 3 patients, HR-QoL stayed stable or went up slightly.
The data for patient 14 from cycle 2 to cycle 11 was missing but according to the TOI score
of cycle 1 and cycle 12-19, he/she seemed to have a relatively stable HR-QoL. The trend
for the TOI scores of each patient in two arms of the clinical mentioned above is displayed
in Figure 3.2.1.
The two-group comparison for the trend of TOI mean scores over cycles was only made
from cycle 1 to cycle 8 (Figure 3.2.2) since fewer patients remained in the study over time
and several patients’ data were missing completely. The total number of patients (listed in
Table 3-2-1) declined to 6 in cycle 9, which was too small to disregard the variance of
individuals within each group. As shown in Figure 3.2.2 (b), there was a slightly upward
trend for the mean score of TOI in the experimental group, while in the control group, the
mean score went down dramatically between cycle 4 and cycle 8. P-values of the t-test (see
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in Table 3-2-1) also suggests that at cycle 1 and cycle 4, there was no significant difference
between the TOI means of two groups while at cycle 5, 6, 7, and 8 (p-value ≈ 0.05) the
difference became significant.

Figure 3.2.1 The TOI scores for each patient

Figure 3.2.2 The means of TOI scores of two treatment groups at each cycle

(a)

(b)
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Table 3-2-1 The number of patients at each cycle when cancer progression happened and the pvalue of the Student’s t-test comparing mean TOI between two groups at different cycles.
No. of patients
CPT-11
CPT-11/YIV-906

cycle 1
11
6

cycle 4
11
7

cycle 5
6
7

cycle 6
6
6

cycle 7
6
5

cycle 8
6
4

cycle
9+
3
3

p-value of mean
TOI comparison

0.3156

0.7080

0.0463

0.0416

0.0284

0.0512

---

*TOI score for patient 17 in CPT-11/YIV-906 arm was missing.

3.3 Metabolites
Of the 72 metabolites, four types of metabolites, referred as Meta 1, Meta 2, Meta 3 and
Meta 4 (as a future potential patent candidate), were significantly (p < 0.05) affected by
YIV-906 intake (Figure 3.3.1).
According to the graphs, for the CPT-11/YIV-906 treatment group, the trends of the means
of all 4 metabolites stayed relatively horizontal or went up slightly over cycles. In
comparison, the means of these metabolites for patients in CPT-11 group tended to
decrease over cycles, some of which even dropped down to 0 at the end. However, these
metabolites fluctuated more among patients who took YIV-906, especially Meta 2, 3, and
4.
The FDR-adjusted p-values of the ANOVA comparison between two treatment groups for
these 4 metabolites are shown in Table 3-3-1.

13

Figure 3.3.1 Four metabolites that were significantly affected by YIV-906 at α=0.05
Meta 1

Meta 2

Meta 3

Meta 4

*treat: 0 --- CPT11; 1 --- CPT11/PHY906
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Table 3-3-1 Row p-value and FDR-adjusted p-value for repeated-measures ANOVA comparison
Number of Meta
Meta 1**
Meta 2**
Meta 3**
Meta 4**

Row P-value
0.000376
0.000466
0.001243
0.001732

FDR Adjusted P-value
0.016789
0.016789
0.023527
0.023527

** significant at level of type I error α=0.05

4. Discussion
The analysis in our study suggests that the botanical formulation YIV-906 could
significantly improve progression-free survival for mCRC patients completing at least
three cycles of irinotecan plus bevacizumab (CPT-11) treatment without cancer
deterioration. YIV-906 also has a great potential to benefit patients’ overall HR-QoL after
first a few cycles of treatment. YIV-906 might be able to prevent the HR-QoL from
reclining due to chemotherapy in the long term, which allows patients to receive proper
doses and duration of the treatment (Figure 3.2.2).
Similar to HR-QoL, the trend of the metabolite levels for two groups also showed that
YIV-906 might have greater effect in the long term. There is no obvious separation of the
metabolite levels at the early stage of the treatment. However, the group of patients taking
YIV-906 in addition to CPT-11 sustains their metabolite profile at the later stage.
Each of these 4 metabolites plays their own role in metabolism. Meta 1 is a very important
element in angiogenesis, methyl donation, and antioxidative effects especially in guts and
livers. Meta 2 and Meta 3 are both known to promote diuresis, and Meta 4 is one of the
fundamental components in metabolism.
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Further studies are needed to explore the relationship between the change of these 4
metabolites and PFS or HR-QoL using more comprehensive data. It may not only be able
to explain the metabolic mechanism of YIV-906’s impact on the quality of life, but also
allow us to screen patients who would not respond to a certain cancer treatment before it
starts or to predict cancer progression during the treatment using biomarkers. Since the
clinical trials of YIV-906 had been designed for cancers at different sites, it would also be
interesting to see if there are any biomarkers that could predict the response result for
multiple types of cancer. However, in order to make a precise prediction, different kinds
of biomarkers, like cytokines, genotypes, and metabolites, should be analyzed
comprehensively in the future.
Nevertheless, the biggest limitations of this study are the small sample size and incomplete
data collection due to the unexpected early close of the clinical trial, especially for HRQoL analysis. Some patients who have a relatively long PFS (more than 160 days) did not
have their HR-QoL recorded at some cycles or at all, which made the analysis hard to
perform. In addition, the follow-up information for HR-QoL as well as metabolites after
cancer progressed should also be collected and evaluated to monitor the changes after the
drug intake stops, which might provide more clues for understanding the role that YIV-906
plays in cancer treatment. Thus, further analysis for the influence YIV-906 on patients’
HR-QoL, metabolites, and the correlation between them should be performed using
additional data from future clinical trials of YIV-906 with proper sample size.
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Appendix A:
Abbrevaitions
SDS (higher=worse)

Instrument
Symptom Distress Scale

Score Interpretation
higher score indicates higher level of
symptom distress

EDT (higher=worse)

Emotional Distress Thermometer

higher score indicates higher level of
emotional distress

fatigue (higher=better)

Functional Assessment of
Chronic Illness Therapy-Fatigue

higher score indicates higher level of
quality of life, i.e. lower level of fatigue

FACIT-D
(higher=better)

the Functional Assessment of
Chronic Illness Therapy-Diarrhea

higher score indicates higher level of
quality of life

FACT-C
(higher=better)

Functional Assessment of Cancer
Therapy-Colorectal

PWB (higher=better)

Physical well-being (subscale)

higher score indicates higher level of
quality of life
high score indicates higher level of
physical well-being

SWB (higher=better)

high score indicates higher level of
social/family well-being

EWB (higher=better)

Social/family well-being
(subscale)
Emotional well-being (subscale)

FWB (higher=better)

Functional well-being (subscale)

high score indicates higher level of
functional well-being

CCS (higher=better)

Colorectal Cancer Subscale

DS (higher=better)

Diarrhea subscale

higher score indicates higher level of
quality of life with respect to the
colorectal specific concerns
higher score indicates higher level of
quality of life with respect to the
diarrhea-related concerns

FACT-G
(higher=better)
TOI (higher=better)

Functional Assessment of
Chronic Illness Therapy-General
Trial Outcome Index

high score indicates higher level of
emotional well-being

higher score indicates higher level of
quality of life
higher score indicates higher level of
quality of life (sum of PWB, FWB and
additional concerns of DS in the
FACIT-D/ or CCS in the FACT-C)
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